Elevate Capital

Adipo Therapeutics is a biotechnology company focused on developing polymer-based nanotherapeutics aimed at treating obesity and type 2 diabetes. The company specializes in notch-inhibiting nanoparticles that are administered through weekly self-injections directly into subcutaneous white adipose tissue. These nanoparticles facilitate the conversion of energy-storing white fat into energy-burning brown fat, leading to significant metabolic changes. This process enhances energy expenditure, promotes weight loss, improves insulin sensitivity, and optimizes fat storage. By leveraging this innovative approach, Adipo Therapeutics seeks to help millions of individuals achieve natural weight loss and restore metabolic balance, ultimately transforming the management of obesity-related diseases.

Phosio specializes in producing unique chemicals that facilitate the creation of metal oxide thin films using ultraviolet (UV) light at very low temperatures. These metal oxides are utilized across various industries, including semiconductors, batteries, optical coatings, and optoelectronic devices such as displays and solar cells. Additionally, Phosio develops photoresist materials designed to manufacture high aspect ratio nanostructures, focusing on low-temperature production of high-refractive-index optical coatings that are UV curable, transparent, and robust. These advancements support the tech hardware industry in developing smart devices for components like augmented reality, organic light-emitting diode (OLED), and light-emitting diode (LED) technologies.

ONEOQ provides Automotive, Smart Lighting, Nano-illumination technology and Lidar, Autonomous Vehicles, and Drone Navigation technology.

Novilytic is a company focused on ensuring the quality of lifesaving medicines through innovative nanotechnology. Its flagship product, the Proteometer, enables drug development companies to monitor molecular structure changes in near real-time, serving as a critical tool in pharmaceutical manufacturing. This technology is designed to be easily integrated into existing processes, allowing customers to quickly convert their liquid chromatography systems into Proteometers without extensive training. The Proteometer provides at-line, real-time batch analysis, eliminating the need for sample preparation and reducing reliance on mass spectrometers. This capability enhances the efficiency of drug development, ultimately aiming to lower costs and improve accessibility to essential medications. Novilytic is supported by a robust intellectual property portfolio, including over 10 patents, and has established partnerships with various analytical instrument companies, pharmaceutical consortiums, and academic institutions. The company’s expert team comprises Ph.D. chemists and engineers dedicated to advancing the field of pharmaceutical manufacturing through cutting-edge science. Commercialization efforts for the Proteometer are underway, with a product launch anticipated in early 2023.

Adipo Therapeutics is a biotechnology company focused on developing polymer-based nanotherapeutics aimed at treating obesity and type 2 diabetes. The company specializes in notch-inhibiting nanoparticles that are administered through weekly self-injections directly into subcutaneous white adipose tissue. These nanoparticles facilitate the conversion of energy-storing white fat into energy-burning brown fat, leading to significant metabolic changes. This process enhances energy expenditure, promotes weight loss, improves insulin sensitivity, and optimizes fat storage. By leveraging this innovative approach, Adipo Therapeutics seeks to help millions of individuals achieve natural weight loss and restore metabolic balance, ultimately transforming the management of obesity-related diseases.

Toralgen, Inc. is a preclinical stage biopharmaceutical company based in Indianapolis, Indiana, focused on the development and commercialization of innovative human therapeutics. Established in 2017, the company specializes in a unique drug delivery technology platform that utilizes polybile nanopill delivery systems. This technology is designed to enhance the oral administration of active drug compounds, ensuring targeted delivery to specific sites within the body. By addressing the challenges associated with oral drug delivery, Toralgen's nanopills aim to improve the efficacy and safety of therapeutic agents, ultimately enhancing patient outcomes in healthcare.

MITO Material Solutions is a specialty chemical company that develops and manufactures graphene-based hybrid polymer modifiers and nano-additives to improve the durability and performance of composite materials. Its product lines include hybridized graphene oxide and epoxide-based modifiers that strengthen fiber-reinforced thermoset and thermoplastic resins, and the E-GO material used in carbon fiber components. The company also markets the T-Series nano-additives, which toughen epoxy and resin systems to increase toughness and reduce material usage. These additives are used in resins and thermoplastics such as PA66 and find applications across aerospace, automotive, wind energy, and transportation sectors, including RVs and boats. MITO was founded in 2016 and is based in Indianapolis, with an additional office in Stillwater, Oklahoma.

Toralgen, Inc. is a preclinical stage biopharmaceutical company based in Indianapolis, Indiana, focused on the development and commercialization of innovative human therapeutics. Established in 2017, the company specializes in a unique drug delivery technology platform that utilizes polybile nanopill delivery systems. This technology is designed to enhance the oral administration of active drug compounds, ensuring targeted delivery to specific sites within the body. By addressing the challenges associated with oral drug delivery, Toralgen's nanopills aim to improve the efficacy and safety of therapeutic agents, ultimately enhancing patient outcomes in healthcare.